The cell engineering technology company has also inked a joint research agreement with a Novartis subsidiary.
Caribou Biosciences, a US-based developer of cell engineering technology has closed an $11m series A round featuring pharmaceutical firm Novartis.
The round also included Fidelity Biosciences, a subsidiary of asset manager Fidelity Investments, venture capital firms Mission Bay Capital and 5 Prime Ventures, and an additional, undisclosed strategic partner.
Caribou’s CRISPR-Cas9 technology, based on research conducted at the Doudna Lab at the University of California, Berkeley, will be used in precision cellular engineering and analysis.
The company has also signed…
